BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract illness (LRTI) in children. Several promising live-attenuated RSV vaccines are in development. Defining additional markers of attenuation could enhance clinical trials. METHODS: We used clinical data, virologic data, and nasal wash (NW) specimens from 20 RSV-naive children enrolled in studies of 4 live-attenuated RSV vaccines. Seven received minimally attenuated cpts248/955 or cpts530/1009 (group 1), 6 received moderately attenuated cpts248/404 (group 2), and 7 received highly attenuated rA2cp248/404/1030/ΔSH (group 3). NW specimens were tested for cytokines and chemokines via an electrochemiluminescence biosensor assay. RESULTS: Group 1 exhibited 1 instance of LRTI and significantly higher rates of fever than groups 2 or 3; there were no significant differences in peak titers of vaccine virus in NW specimens. In contrast, levels of interferon γ, interleukin 1β, interleukin 2, interleukin 6, and interleukin 13 were significantly greater in NW specimens from group 1, compared with those from group 3. Maximum increases in levels of most cytokines occurred after peak viral replication but coincided with clinical illness. CONCLUSIONS: Substantial increases in proinflammatory, antiinflammatory, T-helper 1, T-helper 2, and regulatory cytokines were detected in children who received minimally attenuated live RSV vaccines but not in children who received highly attenuated vaccines. Levels of cytokines in NW specimens may be useful biomarkers of attenuation for live RSV vaccines.
BACKGROUND:Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract illness (LRTI) in children. Several promising live-attenuated RSV vaccines are in development. Defining additional markers of attenuation could enhance clinical trials. METHODS: We used clinical data, virologic data, and nasal wash (NW) specimens from 20 RSV-naive children enrolled in studies of 4 live-attenuated RSV vaccines. Seven received minimally attenuated cpts248/955 or cpts530/1009 (group 1), 6 received moderately attenuated cpts248/404 (group 2), and 7 received highly attenuated rA2cp248/404/1030/ΔSH (group 3). NW specimens were tested for cytokines and chemokines via an electrochemiluminescence biosensor assay. RESULTS: Group 1 exhibited 1 instance of LRTI and significantly higher rates of fever than groups 2 or 3; there were no significant differences in peak titers of vaccine virus in NW specimens. In contrast, levels of interferon γ, interleukin 1β, interleukin 2, interleukin 6, and interleukin 13 were significantly greater in NW specimens from group 1, compared with those from group 3. Maximum increases in levels of most cytokines occurred after peak viral replication but coincided with clinical illness. CONCLUSIONS: Substantial increases in proinflammatory, antiinflammatory, T-helper 1, T-helper 2, and regulatory cytokines were detected in children who received minimally attenuated live RSV vaccines but not in children who received highly attenuated vaccines. Levels of cytokines in NW specimens may be useful biomarkers of attenuation for live RSV vaccines.
Authors: Peter F Wright; Ruth A Karron; Shabir A Madhi; John J Treanor; James C King; Alice O'Shea; Mine R Ikizler; Yuwei Zhu; Peter L Collins; Clare Cutland; Valerie B Randolph; Anne M Deatly; Jill G Hackell; William C Gruber; Brian R Murphy Journal: J Infect Dis Date: 2006-01-19 Impact factor: 5.226
Authors: R A Karron; P F Wright; J E Crowe; M L Clements-Mann; J Thompson; M Makhene; R Casey; B R Murphy Journal: J Infect Dis Date: 1997-12 Impact factor: 5.226
Authors: Ruth A Karron; Peter F Wright; Robert B Belshe; Bhagvanji Thumar; Roberta Casey; Frances Newman; Fernando P Polack; Valerie B Randolph; Anne Deatly; Jill Hackell; William Gruber; Brian R Murphy; Peter L Collins Journal: J Infect Dis Date: 2005-03-01 Impact factor: 5.226
Authors: Federico R Laham; Victor Israele; Javier M Casellas; Alejandro M Garcia; Carlos M Lac Prugent; Scott J Hoffman; Debra Hauer; Bhagvanji Thumar; Maria Ivonne Name; Andres Pascual; Natalia Taratutto; Maria T Ishida; Marcela Balduzzi; Miguelina Maccarone; Susana Jackli; Roberto Passarino; Raul A Gaivironsky; Ruth A Karron; Norberto R Polack; Fernando P Polack Journal: J Infect Dis Date: 2004-05-06 Impact factor: 5.226
Authors: R Malley; J DeVincenzo; O Ramilo; P H Dennehy; H C Meissner; W C Gruber; P J Sanchez; H Jafri; J Balsley; D Carlin; S Buckingham; L Vernacchio; D M Ambrosino Journal: J Infect Dis Date: 1998-12 Impact factor: 5.226
Authors: Christy M Tabarani; Cynthia A Bonville; Manika Suryadevara; Patrick Branigan; Dongliang Wang; Danning Huang; Helene F Rosenberg; Joseph B Domachowske Journal: Pediatr Infect Dis J Date: 2013-12 Impact factor: 2.129
Authors: Seyhan Boyoglu-Barnum; Tatiana Chirkova; Sean O Todd; Thomas R Barnum; Kelsey A Gaston; Patricia Jorquera; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson Journal: J Virol Date: 2014-07-02 Impact factor: 5.103
Authors: José Eduardo Vargas; Renato Puga; Joice de Faria Poloni; Luis Fernando Saraiva Macedo Timmers; Barbara Nery Porto; Osmar Norberto de Souza; Diego Bonatto; Paulo Márcio Condessa Pitrez; Renato Tetelbom Stein Journal: Biomed Res Int Date: 2015-03-22 Impact factor: 3.411